[{"address1": "10 Earlsfort Terrace", "city": "Dublin", "zip": "D02 T380", "country": "Ireland", "phone": "353 1 905 8020", "website": "https://www.muraloncology.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.", "fullTimeEmployees": 107, "companyOfficers": [{"maxAge": 1, "name": "Ms. Caroline J. Loew Ph.D.", "age": 52, "title": "President, CEO & Director", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 303289, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adam D. Cutler B.A.", "age": 48, "title": "CFO, Principal Financial Officer & Principal Accounting Officer", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 496654, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Vicki L. Goodman M.D.", "age": 52, "title": "Chief Medical Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 578342, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maiken  Keson-Brookes", "age": 50, "title": "Chief Legal Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Justin  Levine", "title": "Head of Human Resources & VP of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.64, "open": 3.67, "dayLow": 3.42, "dayHigh": 3.67, "regularMarketPreviousClose": 3.64, "regularMarketOpen": 3.67, "regularMarketDayLow": 3.42, "regularMarketDayHigh": 3.67, "forwardPE": -0.6804734, "volume": 56194, "regularMarketVolume": 56194, "averageVolume": 94226, "averageVolume10days": 90620, "averageDailyVolume10Day": 90620, "marketCap": 58781100, "fiftyTwoWeekLow": 2.88, "fiftyTwoWeekHigh": 6.25, "fiftyDayAverage": 3.3066, "twoHundredDayAverage": 3.833, "currency": "USD", "enterpriseValue": -134842928, "floatShares": 13786802, "sharesOutstanding": 17038000, "sharesShort": 465839, "sharesShortPriorMonth": 494201, "sharesShortPreviousMonthDate": 1724976000, "dateShortInterest": 1727654400, "sharesPercentSharesOut": 0.0273, "heldPercentInsiders": 0.0242, "heldPercentInstitutions": 0.71063006, "shortRatio": 5.72, "shortPercentOfFloat": 0.0273, "bookValue": 12.086, "priceToBook": 0.28545424, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -173296992, "trailingEps": -10.24, "forwardEps": -5.07, "enterpriseToEbitda": 0.801, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "MURA", "underlyingSymbol": "MURA", "shortName": "Mural Oncology plc", "longName": "Mural Oncology plc", "firstTradeDateEpochUtc": 1700836200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "56213005-23be-395c-8a2a-a8485dd4c587", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.45, "targetHighPrice": 18.0, "targetLowPrice": 13.0, "targetMeanPrice": 16.33, "targetMedianPrice": 18.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 204704000, "totalCashPerShare": 12.015, "ebitda": -168398000, "totalDebt": 11080000, "quickRatio": 8.379, "currentRatio": 8.652, "debtToEquity": 5.416, "returnOnAssets": -0.81052, "returnOnEquity": -1.78343, "freeCashflow": -92149376, "operatingCashflow": -159892992, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-24"}]